Symbols / NERV $7.98 +1.79%
NERV Chart
About
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 345.33M |
| Enterprise Value | 69.83M | Income | -293.42M | Sales | — |
| Book/sh | -12.66 | Cash/sh | 7.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -16.62 | PEG | — |
| P/S | — | P/B | -0.63 | P/C | — |
| EV/EBITDA | -4.62 | EV/Sales | — | Quick Ratio | 35.94 |
| Current Ratio | 36.29 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -34.67 | EPS next Y | -0.48 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-11 07:00 | ROA | -13.97% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 43.27M |
| Shs Float | 6.32M | Short Float | 1.08% | Short Ratio | 4.08 |
| Short Interest | — | 52W High | 12.46 | 52W Low | 1.15 |
| Beta | -0.30 | Avg Volume | 122.34K | Volume | 243.86K |
| Target Price | $7.25 | Recom | Hold | Prev Close | $7.84 |
| Price | $7.98 | Change | 1.79% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.25
Mean price target
2. Current target
$7.96
Latest analyst target
3. DCF / Fair value
$7.25
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$7.96
Low
$7.00
High
$7.50
Mean
$7.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-12 | main | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2025-11-06 | main | HC Wainwright & Co. | Neutral → Neutral | $4 |
| 2025-02-26 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-11-06 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-08-07 | main | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-05-02 | main | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2024-02-27 | reit | HC Wainwright & Co. | Neutral → Neutral | $11 |
| 2023-08-02 | main | HC Wainwright & Co. | Neutral → Neutral | $11 |
| 2023-05-16 | reit | HC Wainwright & Co. | Neutral → Neutral | $8 |
| 2023-05-02 | reit | HC Wainwright & Co. | — → Neutral | $8 |
| 2023-03-09 | reit | HC Wainwright & Co. | — → Neutral | $8 |
| 2022-11-10 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2022-10-17 | down | JMP Securities | Market Outperform → Market Perform | — |
- CNS therapies firm Minerva joins Stifel 2026 virtual forum webcast - Stock Titan hu, 12 Mar 2026 11
- HC Wainwright Has Bullish Forecast for NERV Q1 Earnings - MarketBeat Mon, 16 Mar 2026 05
- NERV: HC Wainwright & Co. Raises Price Target to $7.00, Maintains Neutral Rating | NERV Stock News - GuruFocus hu, 12 Mar 2026 12
- Minerva Neurosciences: Q4 Earnings Snapshot - KING5.com Wed, 11 Mar 2026 11
- Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most - Yahoo Finance Mon, 16 Feb 2026 08
- Minerva Neurosciences Stock (NERV) Opinions on $200M Funding Deal | NERV Stock News - Quiver Quantitative ue, 21 Oct 2025 07
- Minerva Neurosciences: Q4 Earnings Snapshot - theheraldreview.com hu, 12 Mar 2026 08
- Minerva readies 2026 trial for drug aimed at schizophrenia’s ‘negative’ symptoms - Stock Titan Wed, 11 Mar 2026 11
- NERV: 2025 net loss reached $293.4M; major financing supports pivotal Phase 3 trial for roluperidone - TradingView Wed, 11 Mar 2026 12
- H.C. Wainwright raises Minerva Neurosciences price target on trial design - Investing.com hu, 12 Mar 2026 11
- Why Is Minerva Neurosciences Stock (NERV) Up 165% Today? - TipRanks ue, 21 Oct 2025 07
- Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Pr - GlobeNewswire ue, 21 Oct 2025 07
- Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who own 55% as well as institutions - simplywall.st Mon, 16 Feb 2026 08
- What is HC Wainwright's Forecast for NERV Q1 Earnings? - MarketBeat Fri, 13 Mar 2026 12
- Minerva Neurosciences stock soars after securing $200 million financing - Investing.com ue, 21 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 266.79K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -294.31M | 4.75M | -23.09M | -25.22M |
| TotalUnusualItems | 891.57K | 1.27M | 1.40M | 529.21K |
| TotalUnusualItemsExcludingGoodwill | 891.57K | 1.27M | 1.40M | 529.21K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -293.42M | 1.44M | -30.01M | -32.11M |
| ReconciledDepreciation | 5.44K | 22.47K | 30.98K | 8.51K |
| EBITDA | -293.42M | 6.02M | -21.69M | -24.69M |
| EBIT | -293.42M | 6.00M | -21.72M | -24.70M |
| NetInterestIncome | -3.10M | -4.56M | -8.28M | -7.41M |
| InterestExpense | 0.00 | 4.56M | 8.28M | 7.41M |
| InterestIncome | 1.44M | 556.95K | 16.52K | |
| NormalizedIncome | -294.31M | 435.23K | -31.40M | -32.64M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -293.42M | 1.44M | -30.01M | -32.11M |
| TotalExpenses | 15.10M | 21.85M | 23.12M | 25.23M |
| TotalOperatingIncomeAsReported | -15.10M | -21.85M | -23.12M | -25.23M |
| DilutedAverageShares | 8.46M | 7.57M | 6.51M | 5.34M |
| BasicAverageShares | 8.46M | 7.57M | 6.51M | 5.34M |
| DilutedEPS | -34.67 | 0.19 | -4.61 | -6.01 |
| BasicEPS | -34.67 | 0.19 | -4.61 | -6.01 |
| DilutedNIAvailtoComStockholders | -293.42M | 1.44M | -30.01M | -32.11M |
| NetIncomeCommonStockholders | -293.42M | 1.44M | -30.01M | -32.11M |
| NetIncome | -293.42M | 1.44M | -30.01M | -32.11M |
| NetIncomeIncludingNoncontrollingInterests | -293.42M | 1.44M | -30.01M | -32.11M |
| NetIncomeContinuousOperations | -293.42M | 1.44M | -30.01M | -32.11M |
| TaxProvision | 0.00 | -1.80M | ||
| PretaxIncome | -293.42M | 1.44M | -30.01M | -32.11M |
| OtherIncomeExpense | -275.22M | 27.85M | 1.40M | 529.21K |
| OtherNonOperatingIncomeExpenses | -276.11M | 26.58M | ||
| GainOnSaleOfSecurity | 891.57K | 1.27M | 1.40M | 529.21K |
| NetNonOperatingInterestIncomeExpense | -3.10M | -4.56M | -8.28M | -7.41M |
| TotalOtherFinanceCost | 3.10M | |||
| InterestExpenseNonOperating | 0.00 | 4.56M | 8.28M | 7.41M |
| InterestIncomeNonOperating | 1.44M | 556.95K | 16.52K | |
| OperatingIncome | -15.10M | -21.85M | -23.12M | -25.23M |
| OperatingExpense | 15.10M | 21.85M | 23.12M | 25.23M |
| ResearchAndDevelopment | 5.76M | 11.90M | 12.71M | 14.65M |
| SellingGeneralAndAdministration | 9.34M | 9.95M | 10.41M | 10.58M |
| GeneralAndAdministrativeExpense | 9.34M | 9.95M | 10.41M | 10.58M |
| OtherGandA | 9.34M | 9.95M | 10.41M | 10.58M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 43.27M | 6.99M | 6.99M | 5.34M |
| ShareIssued | 43.27M | 6.99M | 6.99M | 5.34M |
| TotalDebt | 0.00 | |||
| TangibleBookValue | -155.62M | -40.56M | -43.34M | -34.94M |
| InvestedCapital | -140.75M | -25.69M | -28.46M | -20.02M |
| WorkingCapital | 80.81M | 19.43M | 38.66M | 38.78M |
| NetTangibleAssets | -155.62M | -40.56M | -43.34M | -34.94M |
| CapitalLeaseObligations | 0.00 | |||
| CommonStockEquity | -140.75M | -25.69M | -28.46M | -20.02M |
| TotalCapitalization | -140.75M | -25.69M | -28.46M | -20.02M |
| TotalEquityGrossMinorityInterest | -140.75M | -25.69M | -28.46M | -20.02M |
| StockholdersEquity | -140.75M | -25.69M | -28.46M | -20.02M |
| RetainedEarnings | -688.80M | -395.38M | -396.82M | -366.81M |
| AdditionalPaidInCapital | 548.05M | 369.68M | 368.36M | 346.79M |
| CapitalStock | 4.33K | 699.00 | 699.00 | 534.00 |
| CommonStock | 4.33K | 699.00 | 699.00 | 534.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 238.72M | 62.84M | 85.36M | 75.11M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 236.43M | 60.00M | 82.02M | 73.73M |
| OtherNonCurrentLiabilities | 60.00M | 60.00M | 82.02M | 73.73M |
| PreferredSecuritiesOutsideStockEquity | 4.96M | 0.00 | ||
| DerivativeProductLiabilities | 171.46M | 0.00 | ||
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredTaxesLiabilities | 0.00 | |||
| CurrentLiabilities | 2.29M | 2.84M | 3.34M | 1.38M |
| CurrentCapitalLeaseObligation | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 0.00 | 363.18K | 590.77K | 14.83K |
| PayablesAndAccruedExpenses | 2.29M | 2.47M | 2.75M | 1.36M |
| CurrentAccruedExpenses | 1.65M | 865.82K | 944.33K | 393.08K |
| Payables | 639.71K | 1.61M | 1.81M | 969.67K |
| AccountsPayable | 639.71K | 1.61M | 1.81M | 969.67K |
| TotalAssets | 97.97M | 37.14M | 56.90M | 55.09M |
| TotalNonCurrentAssets | 14.87M | 14.87M | 14.90M | 14.93M |
| GoodwillAndOtherIntangibleAssets | 14.87M | 14.87M | 14.89M | 14.91M |
| OtherIntangibleAssets | 17.03K | 42.57K | 51.08K | |
| Goodwill | 14.87M | 14.87M | 14.87M | 14.87M |
| NetPPE | 0.00 | 5.44K | 10.88K | 16.33K |
| GrossPPE | 16.33K | 0.00 | ||
| OtherProperties | 16.33K | |||
| BuildingsAndImprovements | 0.00 | |||
| Properties | 0.00 | |||
| CurrentAssets | 83.10M | 22.27M | 42.00M | 40.16M |
| OtherCurrentAssets | 697.68K | 806.89K | 989.87K | 3.97M |
| RestrictedCash | 100.00K | 100.00K | 100.00K | 100.00K |
| PrepaidAssets | 1.35M | |||
| CashCashEquivalentsAndShortTermInvestments | 82.30M | 21.36M | 40.91M | 36.09M |
| CashAndCashEquivalents | 82.30M | 21.36M | 40.91M | 36.09M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -13.51M | -19.55M | -14.78M | -24.66M |
| IssuanceOfCapitalStock | 80.00M | 0.00 | 20.00M | 0.00 |
| CapitalExpenditure | -16.33K | |||
| InterestPaidSupplementalData | 0.00 | |||
| EndCashPosition | 82.40M | 21.46M | 41.01M | 36.19M |
| BeginningCashPosition | 21.46M | 41.01M | 36.19M | 60.86M |
| ChangesInCash | 60.94M | -19.55M | 4.82M | -24.66M |
| FinancingCashFlow | 74.45M | 0.00 | 19.60M | -5.00 |
| CashFlowFromContinuingFinancingActivities | 74.45M | 0.00 | 19.60M | -5.00 |
| NetOtherFinancingCharges | -5.55M | -396.29K | -5.00 | 60.00M |
| ProceedsFromStockOptionExercised | 0.00 | |||
| NetPreferredStockIssuance | 80.00M | 0.00 | ||
| PreferredStockIssuance | 80.00M | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 20.00M | 0.00 | 0.00 |
| CommonStockIssuance | 0.00 | 20.00M | 0.00 | 0.00 |
| InvestingCashFlow | 0.00 | 0.00 | 0.00 | -16.33K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -16.33K | 0.00 | |
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | 0.00 | |||
| NetPPEPurchaseAndSale | 0.00 | -16.33K | 0.00 | |
| PurchaseOfPPE | 0.00 | -16.33K | 0.00 | |
| OperatingCashFlow | -13.51M | -19.55M | -14.78M | -24.65M |
| CashFlowFromContinuingOperatingActivities | -13.51M | -19.55M | -14.78M | -24.65M |
| ChangeInWorkingCapital | -632.35K | -320.60K | 4.94M | -4.06M |
| ChangeInOtherWorkingCapital | -3.12M | |||
| ChangeInOtherCurrentLiabilities | 0.00 | -111.23K | ||
| ChangeInOtherCurrentAssets | 0.00 | 3.12M | -3.12M | -36.27K |
| ChangeInPayablesAndAccruedExpense | -741.57K | -503.57K | 1.96M | -1.44M |
| ChangeInAccruedExpense | 317.45K | -306.10K | 1.13M | -557.83K |
| ChangeInPayable | -1.06M | -197.48K | 835.65K | -883.55K |
| ChangeInAccountPayable | -1.06M | -197.48K | 835.65K | -883.55K |
| ChangeInPrepaidAssets | 109.22K | 182.97K | -141.75K | 498.24K |
| OtherNonCashItems | -22.02M | 8.28M | 7.41M | 6.33M |
| StockBasedCompensation | 1.33M | 1.33M | 1.97M | 4.11M |
| AssetImpairmentCharge | 0.00 | 15.20M | ||
| AmortizationOfSecurities | 0.00 | |||
| DeferredTax | -1.80M | |||
| DeferredIncomeTax | -1.80M | |||
| DepreciationAmortizationDepletion | 5.44K | 22.47K | 30.98K | 8.51K |
| DepreciationAndAmortization | 5.44K | 22.47K | 30.98K | 8.51K |
| AmortizationCashFlow | 0.00 | 17.03K | 25.54K | 8.51K |
| AmortizationOfIntangibles | 0.00 | 17.03K | 25.54K | 8.51K |
| Depreciation | 5.44K | 5.44K | 5.44K | 0.00 |
| OperatingGainsLosses | 279.21M | |||
| GainLossOnInvestmentSecurities | 279.21M | |||
| NetIncomeFromContinuingOperations | -293.42M | 1.44M | -30.01M | -32.11M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NERV
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|